Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Solid Tumors × Antiemetics × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Vomiting 1 Sarcoma, Alveolar Soft Part 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Postoperative Nausea and Vomiting 1 Philadelphia Chromosome 1 Neuroendocrine Tumors 1 Neoplastic Cells, Circulating 1 Nausea 1 Metastatic Neuroendocrine Prostate Cancer 1 Medulloblastoma 1 Lymphoma, B-Cell 1 Leukemia, Myeloid, Acute 1 Leukemia, B-Cell 1 Leukemia 1 Hematologic Neoplasms 1 Ependymoma 1 Colorectal Neoplasms 1 Chondrosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Burkitt Lymphoma 1 Bulbo-Spinal Atrophy, X-Linked 1 Advanced Solid Tumors 1

Interventions

Injections 26 Carboplatin 17 Docetaxel 14 pembrolizumab 12 Paclitaxel 11 Bevacizumab 10 durvalumab 8 Nivolumab 8 Cisplatin 8 Fluorouracil 7 Oxaliplatin 6 Leucovorin 6 trifluridine tipiracil drug combination 5 toripalimab 5 tislelizumab 5 linifanib 5 Pemetrexed 5 Capecitabine 5 zimberelimab 4 talazoparib 4 olaparib 4 Panobinostat 4 Itraconazole 4 Irinotecan 4 Gemcitabine 4 Everolimus 4 tremelimumab 3 sotorasib 3 sintilimab 3 fludarabine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06242691 2026-03-06

MK-1200-002

Merck Sharp & Dohme LLC

Phase 1/2 Completed

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡